Malvern, Pennsylvania-based Galera Therapeutics, a biotech company focused on treating cancer patients, has closed $37 million in Series B funding. Novo Ventures led the round with participation from previous backers New Enterprise Associates, Novartis Venture Fund, Correlation Ventures and Galera Angels. In conjunction with the funding, Dr. Thomas Dyrberg, a managing partner of Novo Ventures, has been added to Galera’s board of directors.
{iframe}https://www.pehub.com/2015/10/galera-therapeutics-pulls-in-37-mln-series-b/{/iframe}